Results 111 to 120 of about 38,260 (246)
Obesity Reviews, EarlyView.ABSTRACT Introduction Many survivors of childhood brain tumors face long‐term adverse health outcomes like obesity. Uncertainties surround the effect of interventions to manage obesity‐related outcomes in survivors of childhood brain tumors. The goal of this updated systematic review and meta‐analysis was to provide the best estimate of the treatment ...
David Hart +11 more
wiley +1 more source
Nursing Intervention of Patients With Chemotherapy Induced Nausea and Vomiting
Huli yanjiu, 2003 Objective: to probe into nursing intervention on pat ients with chemotherapy induced nausea and vomiting. Method: a total of 166 malignant tumor patients we re divided into test and control group randomly.
马从凤, 韩忠秀
doaj
Journal of Gandhara Medical and Dental SciencesOBJECTIVES This audit aimed to determine the efficacy of different antiemetic regimens across emetogenic risk levels in managing chemotherapy-induced vomiting and nausea.
Muhammad Umer Khayyam Azam +2 more
doaj +1 more source
Bridging the Gap Between General and Transplant Infectious Disease Practice
Transplant Infectious Disease, EarlyView.ABSTRACT The population of iatrogenic immunocompromised individuals is steadily rising as we continue to improve in our ability to manage diseases, including cancer, autoimmune disease, and end‐organ dysfunction, with increasing access to novel agents and transplantation.
Jeremey Walker +4 more
wiley +1 more source
American Journal of Hematology, Volume 101, Issue 9, Page 2258-2268, September 2026.ABSTRACT Quizartinib is a tyrosine kinase inhibitor with single agent activity in patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) and has demonstrated efficacy in first‐line therapy when combined with intensive chemotherapy in both FLT3 ITD‐negative and positive AML.
Teresa Bernal +29 more
wiley +1 more source
American Journal of Hematology, Volume 101, Issue 9, Page 2288-2296, September 2026.ABSTRACT Dordaviprone is a first‐in‐class small‐molecule imipridone. In preclinical studies, it is active against leukemia cells harboring a TP53 mutation or complex karyotype and leukemia stem cells while sparing normal bone marrow cells. This study aimed to determine the safety of dordaviprone maintenance after allogeneic hematopoietic cell ...
Vijaya Raj Bhatt +8 more
wiley +1 more source
The 9th International RASopathies Symposium
American Journal of Medical Genetics Part A, Volume 200, Issue 8, Page 1934-1941, August 2026.ABSTRACT The RASopathies are a group of congenital disorders with overlapping clinical manifestations that are caused by pathogenic germline or early somatic variants that result in the hyperactivation of the RAS/mitogen‐activated protein kinase (MAPK) signaling pathway.
Pau Castel +41 more
wiley +1 more source
Fatores de risco para náuseas e vômitos pós-operatórios no Hospital Universitário Polydoro Ernanni de São Thiago [PDF]
, 2012 Trabalho de Conclusão de Curso - Universidade Federal de Santa Catarina. Curso de Medicina.
Santos, Michele Caroline
core
Cancer Innovation, Volume 5, Issue 4, August 2026.Antiangiogenic‐based regimens demonstrated superior efficacy compared to chemotherapy alone in heavily pretreated MBC patients, with manageable AEs. ABSTRACT Background The prognosis for metastatic breast cancer (MBC) remains poor, and treatment options are limited for patients with heavily pretreated disease. Although antiangiogenic agents may provide
Yuanyi Wang +6 more
wiley +1 more source
Application of unsupervised learning in clinical oncology practice - exploring anxiety characteristics in chemotherapy-induced nausea and vomiting through principal variables [PDF]
, 2010 State anxiety is a risk factor for chemotherapy-induced nausea and vomiting (CINV). However, anxiety is a subjective symptom and is difficult to quantify in clinical practice. Clinicians need appropriate anxiety measures to assess patients’ risks of CINV.
Yak, Xin Ran +4 more
core